Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BenQ Medical TechnologyROCO:4116 +0.87%86 Debt-to-EBITDA is 2.32 as of Jun. 2026, which is 38% above its 10-year median of 1.68. GuruFocus rates ROCO:4116 with a GF Score™ of 86/100 and a GF Value™ of NT$55.17 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 472 Medical Devices & Instruments companies, BenQ Medical Technology ranks worse than 67.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BenQ Medical Technology's Debt-to-EBITDA or its related term are showing as below:
ROCO:4116'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.87 Med: 1.68 Max: 3.08
Current: 2.75
During the past 13 years, the highest Debt-to-EBITDA Ratio of BenQ Medical Technology was 3.08. The lowest was 0.87. And the median was 1.68.
ROCO:4116's Debt-to-EBITDA is ranked worse than 67.16% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs ROCO:4116: 2.75
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BenQ Medical Technology Debt-to-EBITDA Related Terms
BenQ Medical Technology Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4116 vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, BenQ Medical Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BenQ Medical Technology Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BenQ Medical Technology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BenQ Medical Technology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
BenQ Medical Technology (ROCO:4116) has a Debt-to-EBITDA of 2.32 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BenQ Medical Technology. This is 38% above median its historical median of 1.68. Over the past decade, BenQ Medical Technology's Debt-to-EBITDA has ranged from 0.87 to 3.08. According to the industry distribution chart, BenQ Medical Technology ranks #317 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 67.2%.
Is BenQ Medical Technology's Debt-to-EBITDA too high?
BenQ Medical Technology's current Debt-to-EBITDA of 2.32 is 38% above median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 3.08. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. BenQ Medical Technology's value of 2.32 is 41.9% above this industry median. Based on the distribution chart, BenQ Medical Technology ranks #317 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, BenQ Medical Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BenQ Medical Technology's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, BenQ Medical Technology ranks #317 out of 472 companies for Debt-to-EBITDA. This places BenQ Medical Technology in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. BenQ Medical Technology's value of 2.32 is 41.9% above this benchmark. Historically, BenQ Medical Technology's own Debt-to-EBITDA has ranged from 0.87 to 3.08 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 1.64, BenQ Medical Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BenQ Medical Technology's current Debt-to-EBITDA of 2.32 is 41.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BenQ Medical Technology. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BenQ Medical Technology's current Debt-to-EBITDA is 2.32, which is 38% above median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BenQ Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, BenQ Medical Technology (ROCO:4116) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$55.17, compared to a current price of NT$40.45 — trading 26.7% below its estimated fair value. The current Debt-to-EBITDA is 2.32, which is 38% above median its 10-year median of 1.68 and 41.9% above the Medical Devices & Instruments industry median of 1.64. BenQ Medical Technology's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BenQ Medical Technology (ROCO:4116), the current Debt-to-EBITDA is 2.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BenQ Medical Technology (ROCO:4116) Overvalued in 2026?
Based on GuruFocus' analysis, BenQ Medical Technology stock appears to be undervalued.
The current stock price of NT$40.45 is trading 26.7% below its estimated GF Value™ of NT$55.17.
GuruFocus considers BenQ Medical Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4116:
Debt-to-EBITDA: 2.32 (38% above median its 10-year median of 1.68)
GF Value™: NT$55.17 vs. price of NT$40.45 (26.7% below fair value)
Industry Position: 41.9% above the Medical Devices & Instruments median (#317 of 472)
No single metric tells the full story. See the ROCO:4116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BenQ Medical Technology Corp is engaged in the manufacturing, assembly, maintenance, repair, and sales of professional medical equipment and consumables. Its products include surgical and gynecology tables, digital OR solutions, halogen and LED surgical lights, and medical imaging products, among others. The company's segment includes the R&D and Manufacturing Division and the Medical Services Division. The company generates the majority of its revenue from the Medical Services Division. Geographically, the company generates revenue from Taiwan, Mainland China, Indonesia, Thai, India, Colombia, and Others.
86GF Score
Get the complete analysis for ROCO:4116
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4116 has been successfully added to your 
